News stories about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.8438840661585 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

VNDA has been the topic of a number of recent analyst reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $23.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, June 27th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, September 14th. Jefferies Group LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, August 29th. Zacks Investment Research raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Finally, HC Wainwright set a $18.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $21.63.

Vanda Pharmaceuticals (NASDAQ VNDA) opened at 18.60 on Friday. The firm’s market cap is $834.36 million. The stock’s 50 day moving average price is $16.57 and its 200 day moving average price is $15.25. Vanda Pharmaceuticals has a 52 week low of $12.70 and a 52 week high of $18.85.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The company had revenue of $42.06 million for the quarter, compared to the consensus estimate of $40.31 million. During the same quarter last year, the business posted $0.01 EPS. Vanda Pharmaceuticals’s revenue for the quarter was up 16.7% on a year-over-year basis. On average, equities research analysts predict that Vanda Pharmaceuticals will post ($0.42) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Vanda Pharmaceuticals (VNDA) Earns Daily Media Sentiment Rating of 0.13” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/vanda-pharmaceuticals-vnda-earns-daily-media-sentiment-rating-of-0-13/1584688.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.